- Home
- FLX vs MLYS Comparison
FLX vs MLYS Comparison
Compare FLX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- MLYS
- Stock Information
- Founded
- FLX 2013
- MLYS 2019
- Country
- FLX China
- MLYS United States
- Employees
- FLX N/A
- MLYS N/A
- Industry
- FLX
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- FLX
- MLYS Health Care
- Exchange
- FLX NYSE
- MLYS Nasdaq
- Market Cap
- FLX 603.7M
- MLYS 526.1M
- IPO Year
- FLX 2024
- MLYS 2023
- Fundamental
- Price
- FLX $8.39
- MLYS $10.86
- Analyst Decision
- FLX
- MLYS Strong Buy
- Analyst Count
- FLX 0
- MLYS 2
- Target Price
- FLX N/A
- MLYS $30.00
- AVG Volume (30 Days)
- FLX 18.3K
- MLYS 263.5K
- Earning Date
- FLX 02-27-2025
- MLYS 03-20-2025
- Dividend Yield
- FLX N/A
- MLYS N/A
- EPS Growth
- FLX N/A
- MLYS N/A
- EPS
- FLX 0.19
- MLYS N/A
- Revenue
- FLX $663,142,775.00
- MLYS N/A
- Revenue This Year
- FLX N/A
- MLYS N/A
- Revenue Next Year
- FLX N/A
- MLYS N/A
- P/E Ratio
- FLX $45.81
- MLYS N/A
- Revenue Growth
- FLX 1.31
- MLYS N/A
- 52 Week Low
- FLX $6.50
- MLYS $8.58
- 52 Week High
- FLX $21.95
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- MLYS 51.57
- Support Level
- FLX N/A
- MLYS $9.81
- Resistance Level
- FLX N/A
- MLYS $10.79
- Average True Range (ATR)
- FLX 0.00
- MLYS 0.62
- MACD
- FLX 0.00
- MLYS 0.15
- Stochastic Oscillator
- FLX 0.00
- MLYS 100.00
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.